Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Increases fat oxidation, plasma glycerol levels, and reduces body weight in obese models without affecting glucose metabolism
Tirzepatide is administered as a once-weekly subcutaneous injection, with dosing typically starting at 2.5 mg for 4 weeks, then increasing by 2.5 mg every 4 weeks as tolerated to a maintenance dose of 5, 10, or 15 mg based on individual response
Potential Drug Interactions with Semaglutide Semaglutide, a GLP-1 receptor agonist, can interact with other medications, potentially altering their effectiveness or increasing the risk of side effects
Yes, Obesema 1.7 mg Injection is designed as a pre-filled pen for self-administration at home
10.1038/s41392-021-00656-7 225 WangH
Gray R, Patel S, Ives N, Rick C, Woolley R, Muzerengi S, et al
